ConductScience.org, home

Paper8637232

Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells.

Rosnet O and 10 others. Leukemia, 1996. Cited by 204 papers, by iCite.

Cite this record

ConductScience Library. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Papers, record 8637232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8637232

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells.
PubMed
Journal
Leukemia
PubMed
Year
1996
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
204
iCite
Relative citation ratio, by iCite
3.83
iCite
Revised in PubMed
2013-03-04
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rosnet OO
2Bühring HJH J
3Marchetto SS
4Rappold II
5Lavagna CC
6Sainty DD
7Arnoulet CC
8Chabannon CC
9Kanz LL
10Hannum CC
11Birnbaum DD

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hematopoietic Stem CellsMajor topic
LeukemiaMajor topic
Membrane ProteinsMajor topic
Neoplastic Stem CellsMajor topic
Receptor Protein-Tyrosine KinasesMajor topic
Antibodies, Monoclonal
Antigens, CD34
Burkitt Lymphoma
Cell Membrane
Flow Cytometry
Humans
Leukemia, Myeloid, Acute
Proto-Oncogene Proteins c-kit

Source PubMed

Download CSV of topics

Cited by95

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 204 citations.

PMIDTitleJournalYearIn PapersSource
42434847QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.Future Oncol2026https://conductscience.org/library/papers/42434847PubMed
42305542From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia.Front Immunol2026https://conductscience.org/library/papers/42305542PubMed
41576755Advancements in targeted therapies for acute myeloid leukemia.Curr Opin Pharmacol2026https://conductscience.org/library/papers/41576755PubMed
41324594FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.Blood Adv2026https://conductscience.org/library/papers/41324594PubMed
41310898Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting.Exp Hematol Oncol2025https://conductscience.org/library/papers/41310898PubMed
41097772T-Cell Engagers in Acute Myeloid Leukemia: Molecular Targets, Structure, and Therapeutic Challenges.Cancers (Basel)2025https://conductscience.org/library/papers/41097772PubMed
41046303Elucidating the risk factors and oncogene drivers of acute myeloid leukemia.Hum Cell2025https://conductscience.org/library/papers/41046303PubMed
39337490Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets.Int J Mol Sci2024https://conductscience.org/library/papers/39337490PubMed
39007347FLT3/CD99 Bispecific Antibody-Based Nanoparticles for Acute Myeloid Leukemia.Cancer Res Commun2024https://conductscience.org/library/papers/39007347PubMed
38495876Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.Front Immunol2024https://conductscience.org/library/papers/38495876PubMed
38406539CD117 expression predicted FLT3 mutation in T-cell acute lymphoblastic leukemia.EJHaem2024https://conductscience.org/library/papers/38406539PubMed
38187048Overexpression of ABCB1 confers resistance to FLT3 inhibitor FN-1501 in cancer cells: in vitro and in vivo characterization.Am J Cancer Res2023https://conductscience.org/library/papers/38187048PubMed
37760544Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia.Cancers (Basel)2023https://conductscience.org/library/papers/37760544PubMed
37587502Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.J Hematol Oncol2023https://conductscience.org/library/papers/37587502PubMed
37195589Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia.Curr Treat Options Oncol2023https://conductscience.org/library/papers/37195589PubMed
36762937Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets.Expert Opin Investig Drugs2023https://conductscience.org/library/papers/36762937PubMed
36504722PCW-A1001, AI-assisted de novo design approach to design a selective inhibitor for FLT-3(D835Y) in acute myeloid leukemia.Front Mol Biosci2022https://conductscience.org/library/papers/36504722PubMed
36297550Doxorubicin-Loaded Polymeric Micelles Conjugated with CKR- and EVQ-FLT3 Peptides for Cytotoxicity in Leukemic Stem Cells.Pharmaceutics2022https://conductscience.org/library/papers/36297550PubMed
35923716FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.RSC Med Chem2022https://conductscience.org/library/papers/35923716PubMed
35884458"FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors.Cancers (Basel)2022https://conductscience.org/library/papers/35884458PubMed

See all 95 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
FLT32322Swiss-Prot's referenceshttps://conductscience.org/library/genes/2322NCBI Gene
CD34947PubTator's text mininghttps://conductscience.org/library/genes/947NCBI Gene
KIT3815PubTator's text mininghttps://conductscience.org/library/genes/3815NCBI Gene
RET5979PubTator's text mininghttps://conductscience.org/library/genes/5979NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8637232

GET https://conductscience.org/api/papers/v1/8637232/cited_by?page=2